(Reuters) -Pfizer's gene therapy for hemophilia A significantly cut the number of annual bleeding episodes in patients with the rare disorder in a late-stage study and performed better than the ...
With a positive late-stage trial readout on one gene therapy and E.U. approval for another, Pfizer is closing in on bookending the hemophilia treatment market. To what extent payers will agree to ...
The gene therapy giroctocogene fitelparvovec demonstrated superiority compared with the standard of care, routine prophylaxis, in hemophilia A treatment. Giroctocogene fitelparvovec demonstrated ...
In the spring of 2024, the US Food and Drug Administration (FDA) approved fidanacogene elaparvovec (Beqvez), only the second gene therapy product for hemophilia B. Just a few months later, the Pfizer ...
Gene therapy has been available since 2022 for hemophilia B and since 2023 for hemophilia A, yet some major medical institutions have barely treated any patients so far. What’s the holdup?
A Pfizer gene therapy for hemophilia A reduced bleeding rates in patients with the inherited blood disorder, meeting goals of its Phase 3 study. The preliminary results announced Wednesday are ...
According to multiple media reports on Thursday, Pfizer Inc. (NYSE:PFE) has terminated the global development and commercialization of its hemophilia B gene therapy, Beqvez. In April 2024, the FDA ...
- Based on positive results from Phase 3 AFFINE trial, which met primary and secondary endpoints, Sangamo plans to explore all options to commercialize the asset, including seeking a potential new ...
Hemophilia usually is an inherited bleeding disorder in which the blood does not clot properly. Patients with severe hemophilia A may have to manage their condition with regular at-home injections or ...
PHILADELPHIA, Pa. (Ivanhoe Newswire) - Hemophilia, once a death sentence, is now on the verge of having a cure. An inherited disorder, mostly affecting boys, happens when blood doesn’t clot.
Pfizer said its experimental gene therapy for a rare genetic blood-clotting disorder succeeded in a large late-stage trial, paving the way for a potential approval. The hemophilia A treatment could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results